DISEASE SCANNER

Global Incurable Diseases Tracker

Back to Globe
Rare Disease

Mucopolysaccharidoses (MPS)

HIGH SEVERITY

A group of inherited lysosomal storage disorders caused by deficiency of enzymes needed to break down glycosaminoglycans (GAGs). Seven types (MPS I-VII) with varying severity. Accumulation of GAGs affects multiple organ systems.

Global Affected

15.0K

Countries

15

Symptoms

Coarse facial features
Skeletal dysplasia
Cardiac disease
Respiratory problems
Hepatosplenomegaly
Developmental delay
Corneal clouding

Treatment Options

Specialized care
Supportive treatment
Enzyme replacement
Gene therapy
Clinical trials
Multidisciplinary management
Symptom control

Risk Factors

1Genetic mutations
2Family history
3Consanguinity
4Ethnic predisposition
5De novo mutations

Diagnostic Methods

  • 1Genetic testing
  • 2Specialized biochemical tests
  • 3Imaging
  • 4Biopsy
  • 5Clinical evaluation
  • 6Specialist consultation

Prognosis

Variable; many rare diseases have limited treatment options but research is advancing rapidly. Early diagnosis crucial for optimal management.

Prevention

  • Genetic counseling
  • Carrier screening
  • Prenatal diagnosis
  • Newborn screening
  • Family planning

Research Status

Enzyme replacement therapy for MPS I, II, IVA, VI. Hematopoietic stem cell transplant for severe MPS I, VI, VII. Gene therapy trials ongoing. Elaprase, Aldurazyme, Vimizim approved.

Sources

  • https://rarediseases.org
  • https://www.ncbi.nlm.nih.gov/books/NBK1262
  • https://www.hematology.org/education/patients
  • https://www.ncbi.nlm.nih.gov/books
  • https://rarediseases.org/rare-diseases

Medical Disclaimer

This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.